Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Israel's Teva reaches potential $4.25 bn US opioid settlement

Washington (AFP) - Israeli generic drug maker Teva has reached an agreement in principle to pay $4.25 billion over 13 years to settle a series of court cases over its role in the US opioid epidemic.

AFP

Haleon’s debut suggests it may not be the jewel in GSK’s medicine cabinet

Consumer goods spin-off makes few waves in biggest European listing for more than a decade

The Guardian - UK

The Good News For Moderna's Covid Shot Wasn't Good News For Its Stock

Moderna stock fell Tuesday after the company said its omicron-targeting booster generated antibodies capable of tackling new variants.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Africa CDC signs with Pfizer for COVID pill for African countries

Pfizer will now supply the COVID-19 pill that is highly effective in preventing hospitalisations and deaths.

Al Jazeera

US allows pharmacists to prescribe Pfizer's COVID pill

U.S. pharmacists can now prescribe the leading COVID-19 pill directly to patients

The Independent UK

Pfizer vaccines that target Omicron variant pass first step to approval in Australia

The TGA’s ‘provisional determination’ for two vaccines comes as BA.4 and BA.5 subvariants drive new wave of Covid cases

The Guardian - AU

Horseshoe crabs: 'Living fossils' vital for vaccine safety

Dover (United States) (AFP) - On a bright moonlit night, a team of scientists and volunteers head out to a protected beach along the Delaware Bay to survey horseshoe crabs that spawn in their millions along the US East Coast from late spring to early summer.

AFP

Read news from The Economist, FT, and more,
with one subscription

Novartis Follows Eli Lilly with $1.4 Billion Gene Editing Pact

Precision BioSciences is developing gene editing tools with several potential advantages over CRISPR.

The Street

Moderna confirms two-in-one Covid and flu jab in the works as testing under way

Scientists have developed an alternative to the current separate inoculations with the trial already under

Daily Record

Alzheimer's Stocks Take A Body Blow After Roche's High-Profile Failure

A highly watched Alzheimer's drug from Roche failed in its final-stage test, but shares of Roche stock rose as others tumbled.

Investors Business Daily

Novartis drug combo shows promise in childhood brain cancer

An oral drug combination by Swiss pharmaceuticals company Novartis showed promise in treating a subgroup of patients suffering from a common childhood brain cancer in a trial.

Reuters

Biotech buyout: San Diego's Turning Point Therapeutics sells to Bristol Myers Squibb for $4.1 billion

Bristol Myers Squibb has inked a deal to buy San Diego's Turning Point Therapeutics for $4.1 billion in cash, strengthening the pharmaceutical giant's presence in precision cancer treatments.

Tribune News Service

GlaxoSmithKline Announces $3.3 Billion Buyout To Square Off With Pfizer, Merck

GlaxoSmithKline announced Tuesday a $3.3 billion deal to buy pneumonia vaccine-maker Affinivax. But GSK stock dipped at the close.

Investors Business Daily

Tentative $161.5 million settlement reached in opioid trial

Attorneys for the state of West Virginia and two remaining pharmaceutical manufacturers have reached a tentative $161.5 million settlement

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

GlaxoSmithKline: Dividend Insights

Wednesday marks the last chance for investors to receive the next dividend payout from GlaxoSmithKline (NYSE:GSK).

StockNews.com

How Does the Pharmaceutical Industry Perform During Recessions?

The Fed’s aggressive interest rate hikes and high energy prices will likely fuel recessionary conditions. Moreover, the unexpected decline in GDP in the first quarter indicates a possible economic contraction. Amid such possibilities, the pharmaceutical industry could attract investors’ attention because of the inelastic demand for its products. Today, I…

Benzinga

AbbVie Walks Away From Parkinson's Drug Pact With BioArctic

AbbVie Inc (NYSE:ABBV) has ended a research partnership with Sweden's BioArctic, backing out further development of an experimental Parkinson's disease drug and other related medicines. A clinicaltrials.gov listing for ABBV-0805 says a Phase I study is "Withdrawn (Strategic considerations)." The partnership between AbbVie and BioArctic, which began in 2016, was focused on antibody drugs…

Benzinga

Cancer Drug Maker BeiGene Takes Action to Mitigate Delisting Risk

Key Takeaways: BeiGene has switched auditors for its New York listing to a U.S. company from a Chinese one in a move to comply with U.S. law The change could reduce the company’s threat of being forcibly delisted from the Nasdaq By Doug Young

Get all your
news in one place.

100’s of premium titles.
One news app.

Axios

Biden's looming prescription drug pricing dilemma

Pressure is increasing on the administration to go after drug patents.

Asharq Al-Awsat

New Cancer Immunotherapy Fails in First Roche Trial

A highly anticipated new cancer immunotherapy by Roche failed to slow the progression of an aggressive form of lung cancer, the Swiss drug maker said on Wednesday, boding ill for a range of rival drug developers working on similar compounds. The Skyscraper 2 trial was the first to produce results…

Investors Business Daily

Why BeiGene — And 2 Other China-Based Biotechs — Are In Trouble

Regulators started a two-year clock Thursday to force China-based companies to comply with U.S. trading rules — leading three biotech stocks to crumble.

StockNews.com

Bristol Myers Squibb is Soaring, and the Stock is Still Cheap

Bristol Myers Squibb's (BMY) outstanding clinical and operational performance, as well as the current momentum across its product portfolio, have enabled the biopharmaceutical concern to post stable revenue growth in its most recent quarterly earnings release. In addition, the stock is currently trading at a discounted valuation despite generating substantial…

AAP

CSL profit falls due to pandemic curbs

Blood products giant CSL says that its ability to collect plasma has been improving as social mobility increases.

Los Angeles Times

Michael Hiltzik: The government could force a price cut for this prostate cancer drug by as much as 80%. Why hasn't it acted?

Xtandi, a wonder drug for prostate cancer, was developed at UCLA with substantial funding from the taxpayers through the Pentagon and the National Institutes of Health.

Crikey

Revealed: Queensland Labor’s secret $10 million investment in CSL shares

The Australian Electoral Commission is about to release its annual political donations data. Journalists will have a field day if they know where to look.

1 … 139 140 141 142

People

Joe Biden

63,652 stories

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.